Short description
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Description
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.
Last funding
Nopepepe
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Boston, Massachusetts, United States, North America
Founded on
February 1, 2010
Exited on
October 5, 2017
Went public on
October 5, 2017
Stock symbol
RYTM
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noway Youcantaccess, Nopepepe, Cannot Access, Noway Youcantaccess, Uh Ohhhh, Cannot Access, Blurry Noaccess, Uh Ohhhh
Sign in for full access
Founders
Bart Henderson, Elizabeth Stoner